1. MiR-29c alleviates hyperglycemia-induced inflammation via targeting TGF-β in cardiomyocytes.
- Author
-
Zhong H, Tang H, Wang Y, Tang S, and Zhu H
- Subjects
- Animals, Mice, 3' Untranslated Regions, Cell Line, Oxidative Stress, Reactive Oxygen Species metabolism, Diabetic Cardiomyopathies metabolism, Diabetic Cardiomyopathies pathology, Diabetic Cardiomyopathies genetics, Hyperglycemia metabolism, Hyperglycemia genetics, Inflammation metabolism, Inflammation genetics, Inflammation pathology, MicroRNAs genetics, MicroRNAs metabolism, Myocytes, Cardiac metabolism, Myocytes, Cardiac pathology, Transforming Growth Factor beta metabolism
- Abstract
This study aims to investigate whether miR-29c is involved in regulating transforming growth factor-β (TGF-β) mediated inflammation in diabetic cardiomyopathy (DCM). Our data showed increased inflammation and oxidative stress in diabetic myocardium together with decrease of miR-29c and elevation of TGF-β expression. In vitro experiments, we transfected miR-29c mimic and antagomir into HL-1 cells to explore the effect of miR-29c on inflammation in hyperglycemic conditions. Overexpression of miR-29c down-regulated the elevated TNF-α level, ROS production and NADPH oxidase activity which caused by high glucose. However, above changes were reversed by miR-29c antagomir. Interestingly, TGF-β protein rather than mRNA expression was changed significantly after transfection with miR-29c mimic, indicating that the modulation of TGF-β mediated by miR-29c was at the posttranslational level. Meanwhile, we found that 3'-UTR of TGF-β was the direct target of miR-29c confirmed by dual-luciferase assay. In conclusion, our study revealed that miR-29c could alleviate hyperglycemic-induced inflammation and ROS production via targeting TGF-β in cardiomyocytes, which provides a potential target for the treatment of DCM., (© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.)
- Published
- 2024
- Full Text
- View/download PDF